The Clinicopathological Significance of BRI3BP in Women with Invasive Breast Cancer

Overview

Journal Transl Cancer Res

Date 2025 Jan 16

PMID 39816562

Authors

Abrar I Aljohani

Ieman A Aljahdali

Ohud A Alsalmi

Meshari A Alsuwat

Abdulaziz A Alsharif

Khalid J Alzahrani

Batool S Alsaleh

Ameen Nadheef

Turki S Alqurashi

Affiliations

Soon will be listed here.

Abstract

Background: Invasive breast cancer (BC) is a highly life-threatening disease affecting women world-wide. While its early identification may benefit the provision of more effective therapies, several BC-associated factors may influence BC patients' therapeutic outcomes. Therefore, identifying novel prognostic and therapeutic targets for invasive BC can help with accurate prognosis and therapy-related decisions. The BRI3 binding protein () gene was found to be a principal gene in invasive BC cohorts using artificial neural network (ANN) techniques. Thus, this study aimed to evaluate the clinicopathological significance of BRI3BP at the transcriptomic and proteomic levels in invasive BC.

Methods: Two transcriptomic BC cohorts, the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC; n=1,980) and The Cancer Genome Atlas (TCGA; n=854), were used to evaluate BRI3BP expression at the mRNA level. Formalin-fixed paraffin-embedded (FFPE) tissues from an invasive BC cohort (n=100) were also used to evaluate BRI3BP expression at the protein level via immunohistochemistry. The association between BRI3BP expression, clinicopathological characteristics, and patient outcomes was evaluated.

Results: In both METABRIC and TCGA cohorts, high expression of was significantly associated with aggressive tumor features such as high histological grade, large tumor size, and lymph vascular invasion (LVI) positivity. At the protein level, high BRI3BP expression was associated with high histological grade, hormone receptor negativity, high expression of Ki67, and poor outcome.

Conclusions: This study revealed the prognostic significance of BRI3BP in invasive BC patients. Further functional assessment is needed to confirm the biological role of BRI3BP in BC.

References

Yamazaki T, Sasaki N, Nishi M, Yamazaki D, Ikeda A, Okuno Y . Augmentation of drug-induced cell death by ER protein BRI3BP. Biochem Biophys Res Commun. 2007; 362(4):971-5. DOI: 10.1016/j.bbrc.2007.08.082. View

Klebe M, Fremd C, Kriegsmann M, Kriegsmann K, Albrecht T, Thewes V . Frequent Molecular Subtype Switching and Gene Expression Alterations in Lung and Pleural Metastasis From Luminal A-Type Breast Cancer. JCO Precis Oncol. 2020; 4. PMC: 7446514. DOI: 10.1200/PO.19.00337. View

Fumagalli C, Barberis M . Breast Cancer Heterogeneity. Diagnostics (Basel). 2021; 11(9). PMC: 8468623. DOI: 10.3390/diagnostics11091555. View

Shin S, Chung Y, Oh S, Jeon H, Hwang L, Namkoong H . HCCR-1-interacting molecule "deleted in polyposis 1" plays a tumor-suppressor role in colon carcinogenesis. Gastroenterology. 2006; 130(7):2074-86. DOI: 10.1053/j.gastro.2006.03.055. View

Liu Y, Beyer A, Aebersold R . On the Dependency of Cellular Protein Levels on mRNA Abundance. Cell. 2016; 165(3):535-50. DOI: 10.1016/j.cell.2016.03.014. View

Lindstrom L, Yau C, Czene K, Thompson C, Hoadley K, Vant Veer L . Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer. J Natl Cancer Inst. 2018; 110(7):726-733. PMC: 6037086. DOI: 10.1093/jnci/djx270. View

Ha S, Shin S, Lee Y, Kim S, Kim H, Namkoong H . HCCRBP-1 directly interacting with HCCR-1 induces tumorigenesis through P53 stabilization. Int J Cancer. 2007; 122(3):501-8. DOI: 10.1002/ijc.23146. View

Prabahar A, Zamora R, Barclay D, Yin J, Ramamoorthy M, Bagheri A . Unraveling the complex relationship between mRNA and protein abundances: a machine learning-based approach for imputing protein levels from RNA-seq data. NAR Genom Bioinform. 2024; 6(1):lqae019. PMC: 10858678. DOI: 10.1093/nargab/lqae019. View

Liao S, Liang L, Yue C, He J, He Z, Jin X . CD38 is involved in cell energy metabolism via activating the PI3K/AKT/mTOR signaling pathway in cervical cancer cells. Int J Oncol. 2020; 57(1):338-354. DOI: 10.3892/ijo.2020.5040. View

10.

Jeon T, Kim A, Kim C . Automated immunohistochemical assessment ability to evaluate estrogen and progesterone receptor status compared with quantitative reverse transcription-polymerase chain reaction in breast carcinoma patients. J Pathol Transl Med. 2020; 55(1):33-42. PMC: 7829576. DOI: 10.4132/jptm.2020.09.29. View

11.

Aljohani A, Toss M, El-Sharawy K, Mirza S, Ball G, Green A . Upregulation of Cyclin B2 () in breast cancer contributes to the development of lymphovascular invasion. Am J Cancer Res. 2022; 12(2):469-489. PMC: 8899993. View

12.

Wang M, Zhang C, Song Y, Wang Z, Wang Y, Luo F . Mechanism of immune evasion in breast cancer. Onco Targets Ther. 2017; 10:1561-1573. PMC: 5359138. DOI: 10.2147/OTT.S126424. View

13.

Zhang Y, Wang X, Hu C, Yi H . Shiny transcriptional junk: lncRNA-derived peptides in cancers and immune responses. Life Sci. 2023; 316:121434. DOI: 10.1016/j.lfs.2023.121434. View

14.

Zhu L, Ma P, Hu Y, Feng Y, Li P, Wang H . HCCR-1 is a Novel Prognostic Indicator for Gastric Cancer and Promotes Cell Proliferation. J Cancer. 2019; 10(15):3533-3542. PMC: 6603419. DOI: 10.7150/jca.22462. View

15.

Halabi S, Owzar K . The importance of identifying and validating prognostic factors in oncology. Semin Oncol. 2010; 37(2):e9-18. PMC: 2929829. DOI: 10.1053/j.seminoncol.2010.04.001. View

16.

Liu X, Haniff H, Childs-Disney J, Shuster A, Aikawa H, Adibekian A . Targeted Degradation of the Oncogenic MicroRNA 17-92 Cluster by Structure-Targeting Ligands. J Am Chem Soc. 2020; 142(15):6970-6982. PMC: 7357852. DOI: 10.1021/jacs.9b13159. View

17.

Dai X, Xiang L, Li T, Bai Z . Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes. J Cancer. 2016; 7(10):1281-94. PMC: 4934037. DOI: 10.7150/jca.13141. View

18.

Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi M, Moradi-Kalbolandi S . Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol. 2020; 84:106535. DOI: 10.1016/j.intimp.2020.106535. View

19.

Lv Q, Meng Z, Yu Y, Jiang F, Guan D, Liang C . Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer. Int J Mol Sci. 2016; 17(12). PMC: 5187895. DOI: 10.3390/ijms17122095. View

20.

Ko J, Shin S, Oh Y, Lee Y, Ryoo Z, Han Lee Y . Transgenic mouse model for breast cancer: induction of breast cancer in novel oncogene HCCR-2 transgenic mice. Oncogene. 2003; 23(10):1950-3. DOI: 10.1038/sj.onc.1207356. View